BioSpace News Archive

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of up to 8,500,000 common shares (the “Common Shares”) of the Company (the “Offering”)

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio will be presented at the 14th Annual PAINWeek National Conference taking place virtually September 11-13th.

Alkermes plc (Nasdaq: ALKS) announced today that that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 16, 2020 at 10:40 a.m. ET (3:40 p.m. BST)

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced further STRO-002 updated interim Phase 1 safety and preliminary efficacy data in ovarian cancer,

TherapeuticsMD Announces Patent Updates for ANNOVERA ® New patents expand U.S. patent protection for ANNOVERA BOCA RATON, Fla.--( BUSINESS WIRE )-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced patent updates for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-controlled, procedure-free, reversible prescription contraceptive option for women

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 4:40 p.m. ET / 1:40 p.m. PT. A live webcast will be available under “Events & Presentations” in

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the upcoming H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15, at 12:00

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it will be featured in a live webinar hosted by Ben Haynor, CFA, Managing Director, Healthcare Research at Alliance Global Partners, on September 15, 2020 at 10:30 a.m. Eastern Time. The

Intensity Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of solid cancers, today announced that the first patients have been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy in Phase 2, KEYNO